Autopsy report · NCT05243524

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

“Closure of IMV operations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Sponsor type

Industry

Conditions

Platinum-resistant Epithelial Ovarian Cancer

Interventions

Maveropepimut-S; Cyclophosphamide 50mg

Participants

16

Sites

6

Countries

Canada, Puerto Rico, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.